The largest, most rigorous clinical trial of psilocybin investigated it as a treatment option for patients with treatment-resistant depression (TRD). The study used COMP360 which is a “proprietary formulation of synthetic psilocybin administered in conjunction with psychological support.” The study found that “25mg COMP360 psilocybin with psychological support led to a statistically and clinically significant reduction in symptoms of depression in people with TRD compared to 1mg at week 3.” These findings are important as it may provide more treatment options for individuals who cannot or do not want to take anti-depressants currently offered.